University of Liverpool

Liverpool School of Tropical Medicine

Other

Abbvie Inc.

Eisai R&d Management Co., Ltd.

Stephen Andrew Ward

Paul Michael O'Neill

Mark John Taylor

Dale J Kempf

Thomas W Von Geldern

Kennan C Marsh

Farid Benayoud

Giancarlo A Biagini

Brian Kevin Park

Louise Ford

Paul Anthony Stocks

Gemma L Nixon

Joseph Turner

Weiqian David Hong

The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds

The present invention relates to a combination therapeutic product comprising one or more respiratory electron transport chain inhibitors and a cytochrome bd inhibitor, as defined herein, or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical compositions comprising the combination therapeutic product and to the use of the combination therapeutic product in the treatment of mycobacterial infections, such as tuberculosis.

Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor

The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.

Treatment of filarial diseases

The present invention relates to pharmaceutical compounds for use in the treatment or porphylaxis of malaria having the general formula: where: R is selected from the group consisting of dimethylamino, diethylamino, di-N-propylamino, diisopropylamino, di-N-butylamino, di-sec-butylamino, piperidinyl, piperizinyl, ethylamino, tert-butylamino; and X is selected from the group consisting of chloro, fluoro, iodo, bromo, trifluoromethyl, methoxy and methyl.

Anti-malarial compounds

Growing community of inventors

Liverpool, United Kingdom

Stephen Andrew Ward